Form 4: Avid Bioservices Director Esther M. Alegria Disposes of Shares, Options, and RSUs in Merger

Director Esther M. Alegria reports the disposal of common stock, stock options, and restricted stock units due to the merger of Avid Bioservices, Inc. with Space Mergerco, Inc.

Summary

• Esther M. Alegria, a director of Avid Bioservices, Inc. (CDMO), reported the disposal of her holdings in the company on February 5, 2025, due to the merger with Space Mergerco, Inc.
• The transaction involved the disposal of 37,746 shares of common stock, 8,376 stock options, and 8,147 restricted stock units (RSUs).
• The merger agreement, dated November 6, 2024, stipulated that each share of common stock would be converted into the right to receive $12.50 in cash.
• Vested stock options were converted into the right to receive a cash payment equal to the difference between $12.50 and the exercise price of $26.03, multiplied by the number of shares subject to the option.
• Unvested RSUs were converted into the right to receive a cash payment of $12.50 per share.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports the factual disposal of securities due to a merger. The financial outcome for the director depends on the terms of the merger agreement, but the announcement itself is neither overtly positive nor negative.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects a merger and acquisition activity within the bioservices industry, where companies may consolidate to achieve greater scale, efficiency, or market reach. Mergers can be driven by factors such as the desire to expand service offerings, geographic footprint, or technological capabilities.

Comparison to Industry Standards

• It's difficult to compare this specific transaction to industry standards without knowing the specific financial details and strategic rationale behind the merger.
• However, mergers in the biopharmaceutical and contract development and manufacturing organization (CDMO) sectors are often valued based on multiples of revenue, EBITDA, or other key financial metrics.
• Comparable companies in the CDMO space include Catalent, Lonza, and Thermo Fisher Scientific, which have been involved in various acquisitions and strategic partnerships.
• The $12.50 per share merger consideration would need to be assessed against Avid Bioservices' historical trading prices and financial performance to determine if it represents a fair value for shareholders.

Stakeholder Impact

• Shareholders received $12.50 per share as part of the merger agreement.
• Employees may experience changes as a result of the merger, depending on the integration plans of the acquiring company.
• The merger could impact customers and suppliers depending on the strategic direction of the combined entity.

Key Dates

Keywords

Merger, Avid Bioservices, CDMO, Form 4, Director, Alegria, Stock Options, RSUs, Beneficial Ownership